BigenCell Presents Preclinical Study Results of Atopic Dermatitis Treatment 'VM-AD' at American Immunology Society
[Asia Economy Reporter Lee Gwan-joo] VigenCell announced on the 9th (local time) that it presented preclinical research results of 'VM-AD,' a treatment under development for atopic dermatitis, at the American Association of Immunologists (AAI) scientific conference.
VigenCell reported that human umbilical cord blood-derived myeloid-derived suppressor cells (hUCB MDSC) showed efficacy in an atopic dermatitis animal model (NC/Nga mice).
The main content was that administering hUCB MDSC to an atopic dermatitis mouse model induced by house dust mites alleviated symptoms of atopic dermatitis by suppressing the activity of inflammatory cytokines such as serum IgE (immunoglobulin E), IL-4, IL-5, and IL-13.
Hot Picks Today
"Buy on Black Monday"... Japan's Nomura Forecasts 590,000 for Samsung, 4 Million for SK hynix
- "Plunged During the War, Now Surging Again"... The Real Reason Behind the 6% One-Day Silver Market Rally [Weekend Money]
- "Not Everyone Can Afford This: Inside the World of the True Top 0.1% [Luxury World]"
- "We're Now Earning 10 Million Won a Month"... Semiconductor Boom Drives Performance Bonuses at Major Electronic Component Firms
- Experts Are Already Watching Closely..."Target Stock Price 970,000 Won" Now Only the Uptrend Remains [Weekend Money]
Tae-gyu Kim, CEO of VigenCell, said, “We will strive to develop this research further to offer new treatment alternatives to atopic dermatitis patients worldwide,” adding, “We will do our best to achieve meaningful results such as licensing out through continuous research and development of ‘VM-AD.’”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
